Pharming Group (NASDAQ:PHAR) Expected to Announce Earnings of $0.01 Per Share

Equities analysts expect Pharming Group (NASDAQ:PHAR) to post earnings of $0.01 per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Pharming Group’s earnings, with the lowest EPS estimate coming in at $0.00 and the highest estimate coming in at $0.01. Pharming Group posted earnings of $0.13 per share in the same quarter last year, which indicates a negative year-over-year growth rate of 92.3%. The firm is expected to issue its next earnings report on Thursday, March 3rd.

According to Zacks, analysts expect that Pharming Group will report full year earnings of $0.03 per share for the current financial year, with EPS estimates ranging from $0.02 to $0.03. For the next year, analysts expect that the company will post earnings of $0.04 per share, with EPS estimates ranging from $0.01 to $0.07. Zacks’ earnings per share averages are an average based on a survey of research firms that follow Pharming Group.

Separately, Zacks Investment Research upgraded shares of Pharming Group from a “hold” rating to a “buy” rating and set a $9.75 price objective for the company in a research note on Tuesday, December 28th.

An institutional investor recently raised its position in Pharming Group stock. Jane Street Group LLC boosted its stake in shares of Pharming Group (NASDAQ:PHAR) by 37.6% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 17,441 shares of the company’s stock after acquiring an additional 4,767 shares during the quarter. Jane Street Group LLC’s holdings in Pharming Group were worth $164,000 as of its most recent SEC filing. Institutional investors own 0.04% of the company’s stock.

NASDAQ:PHAR opened at $9.26 on Wednesday. Pharming Group has a one year low of $7.58 and a one year high of $15.14. The company has a fifty day moving average price of $8.66 and a 200 day moving average price of $9.76. The company has a current ratio of 5.18, a quick ratio of 4.65 and a debt-to-equity ratio of 0.73.

Pharming Group Company Profile

Pharming Group N.V., a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema.

See Also: Calculate Your Return on Investment (ROI)

Get a free copy of the Zacks research report on Pharming Group (PHAR)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with's FREE daily email newsletter.